Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
About this study
The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)
- Condition
- Sickle Cell Disease, Measles Vaccination, Sickle Cell Anemia
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Who can join
- Age
- 0.5 to 6 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 0.5 years
- Maximum age: 6 years
- Study condition: Sickle Cell Disease, Measles Vaccination, Sickle Cell Anemia
- Participants with confirmed Sickle Cell Disease.
- Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
- Willing and able to provide informed consent
- Ability to comply with study related evaluations and follow-up visits.
Exclusion 1
- \. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.
Where
3 sites, 3 recruiting
Korle Bu Teaching Hospital
Accra, Ghana, Ghana
Bugando Medical Centre
Mwanza, Tanzania
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Contact
-
Teresa Latham
513-803-7922 Teresa.Latham@cchmc.org
-
Amy Shova
(513) 803-1917 Amy.Shova@cchmc.org
Potential match only. Final eligibility is determined by the study team.